Information Provided By: 
Fly News Breaks for September 12, 2017
ICPT
Sep 12, 2017 | 10:38 EDT
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
